Starting January 1, 2026, Medicare beneficiaries will see a significant reduction in the cost of ten high-cost prescription drugs, thanks to the Inflation Reduction Act. This change comes as Medicare gains the ability to negotiate drug prices, a move aimed at lowering expenses for both enrollees and the program itself. Here’s a closer look at the medications affected and what this means for you.
Key Medications with Reduced Costs
Eliquis
Eliquis is widely used to prevent and treat blood clots. With its high demand and lack of generic alternatives, the negotiated price reduction will be a welcome relief for many Medicare beneficiaries.
Jardiance
Jardiance is prescribed for managing type 2 diabetes and heart failure. The price reduction will help many patients manage their conditions more affordably.
Xarelto
Similar to Eliquis, Xarelto is another essential medication for blood clot prevention and treatment, and its reduced cost will benefit many.
Januvia
Januvia is a popular medication for treating type 2 diabetes. The price cut will make it more accessible to those who rely on it for managing their blood sugar levels.
Farxiga
Farxiga serves multiple purposes, including treatment for type 2 diabetes, heart failure, and chronic kidney disease. The price reduction is expected to ease the financial burden on patients using this versatile drug.
Entresto
Entresto is a key medication for heart failure treatment. Its inclusion in the price negotiation list will help many patients afford their necessary treatment.
Enbrel
Used for rheumatoid arthritis and psoriasis, Enbrel’s price reduction will be significant for patients who depend on it for managing chronic conditions.
Imbruvica
Imbruvica treats certain blood cancers, and its reduced cost will be critical for patients requiring this life-saving medication.
Stelara
Stelara is used for psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The price cut will make it more accessible for patients with these conditions.
NovoLog/Fiasp
These insulin products are essential for diabetes management, and the price reduction will be a significant relief for many diabetic patients.
Impact on Medicare Beneficiaries
The selection of these medications for price negotiation was based on their high Medicare Part D spending and the absence of generic or biosimilar alternatives. The expected reduction in costs will not only benefit individuals by making these essential drugs more affordable but also help reduce overall spending within the Medicare program.
For Medicare beneficiaries, this change represents a significant step toward more affordable healthcare. It underscores the importance of staying informed about changes in healthcare policies and how they can impact your coverage and costs.
If you have questions about how these changes might affect your Medicare plan or need assistance navigating your options, don’t hesitate to reach out to our agency. We’re here to provide guidance and support to ensure you get the most out of your healthcare coverage.
